China Medical System (HKG:0867) signed a license, collaboration, and distribution agreement with Alpha Cognition for its Zunveyl drug for mild to moderate dementia from Alzheimer's disease, according to a Wednesday filing with the Hong Kong Exchange.
Under the agreement, CMS will have exclusive rights to develop, register, manufacture, import, export, and commercialize the drug in Asia ex-Japan, Australia, and New Zealand, the filing said.
AlphaCognition will still manufacture and supply the drug in Australia and New Zealand, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。